ALEX2 Comprehensive Allergy Panel — 295 Allergens

The ALEX2 Comprehensive Allergy Panel tests IgE reactivity against 295 allergens — 117 standardised extract-level allergens plus 178 molecular (component-resolved) allergens — in a single blood sample. This is the most extensive allergy testing methodology available outside of specialist immunology centres, covering pollen (grasses, trees, weeds), house dust mites, pet dander, moulds, and a wide range of food allergens. By testing both extract-level and molecular allergen components simultaneously, ALEX2 distinguishes true primary sensitisation from cross-reactive false positives — a critical advantage over skin-prick testing or single-allergen IgE panels. Results within 1–2 weeks require physician interpretation to translate the 295 results into a meaningful clinical picture.

Allergic disease affects approximately 40% of the European population and is increasing in prevalence due to environmental changes, dietary shifts, and the hygiene hypothesis. Accurate identification of the causative allergens — rather than empirical avoidance of broad food categories or environments — enables targeted allergen avoidance, specific immunotherapy planning, and informed decision-making about dietary restrictions. The ALEX2 allergy microarray, used by IFCOR Jihlava, tests specific IgE (the immune antibody mediating allergic responses) against 295 allergen components in a single 250 µL blood sample. The platform combines classical allergen extracts (standardised mixtures of proteins from a given source, such as birch pollen or cat epithelium) with purified or recombinant molecular allergen components — individual proteins such as Bet v 1 (the major birch allergen), Fel d 1 (major cat allergen), Ara h 2 (peanut storage protein), or Der p 1 (house dust mite). This dual approach enables component-resolved diagnosis (CRD): a patient reactive to birch pollen extract who also reacts to Bet v 1 has true primary sensitisation; a patient reactive only to extract but not the major molecular component may have cross-reactivity from unrelated pollen. Cross-reactive carbohydrate determinants (CCDs), a major source of false-positive IgE results in standard testing, can also be identified. The 295-component breadth covers inhalant allergens (grass pollens, tree pollens, weed pollens, house dust mites, cockroach, animal danders, moulds, latex), food allergens (nuts, seeds, legumes, cereals, fruits, vegetables, seafood, milk, eggs, soy, meat), and insect venoms. The resulting report identifies sensitisation patterns that guide immunotherapy suitability, cross-reactive allergen relationships, and genuine dietary restrictions versus spurious IgE positivity. Physician interpretation is required to prioritise clinically relevant sensitivities from the breadth of data.